# Blood-borne Assessment of Stromal Activation in Esophageal Adenocarcinoma to Guide Tocilizumab Therapy

> **NCT04554771** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)** · enrollment: 41 (actual)

## Conditions studied

- Esophageal Adenocarcinoma
- Oesophageal Adenocarcinoma
- Resectable Carcinoma

## Interventions

- **DRUG:** Tocilizumab 20 Mg/mL Intravenous Solution
- **DRUG:** Paclitaxel
- **DRUG:** Carboplatin
- **RADIATION:** External beam radiotherapy

## Key facts

- **NCT ID:** NCT04554771
- **Lead sponsor:** Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-01-27
- **Primary completion:** 2022-10-10
- **Final completion:** 2028-04-10
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2024-07-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04554771

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04554771, "Blood-borne Assessment of Stromal Activation in Esophageal Adenocarcinoma to Guide Tocilizumab Therapy". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT04554771. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*